Effect of Rebamipide Ophthalmic Suspension on Optical Quality in the Short Break-up Time Type of Dry Eye

Koh, Shizuka; Inoue, Yasushi; Sugmimoto, Toshiki; Maeda, Naoyuki; Nishida, Kohji

doi:10.1097/ico.0b013e318294f97e

Cited by 52 publications

(49 citation statements)

References 26 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Koh et al60 reported finding significant increases in the tear film break-up time, and there were significant upward curves from the baseline in terms of the total corneal higher-order aberrations, coma-like aberrations, and spherical-like aberrations after the application of rebamipide (Figure 4). In addition, their study demonstrated that rebamipide improved tear stability, possibly leading to improved optical quality.…”

Section: Rebamipide For Clinical Applicationmentioning

confidence: 94%

See 1 more Smart Citation

Rebamipide ophthalmic suspension for the treatment of dry eye syndrome: a critical appraisal

Kashima¹,

Itakura²,

Akiyama³

et al. 2014

OPTH

View full text Add to dashboard Cite

Rebamipide was initially developed and approved for use in treating gastric ulcers and lesions associated with gastritis. Discovery of its ability to increase gastric mucin led to investigations of its effect on ocular surface mucin and the subsequent development for use in dry eye patients. Investigations have confirmed that rebamipide increases corneal and conjunctival mucin-like substances along with improving corneal and conjunctival injury. Clinically, rebamipide ophthalmic suspensions can effectively treat tear deficiency and mucin-caused corneal epithelial damage, and can restore the microstructure responsible for tear stability. Topical rebamipide has also been shown to be effective in treating other ocular surface disorders such as lagophthalmos, lid wiper epitheliopathy, and persistent corneal erosion. Rebamipide’s ability to modify epithelial cell function, improve tear stability, and suppress inflammation in the absence of any known major side effects suggest that it may be a beneficial first drug of choice for severe dry eye treatment and other ocular surface disorders. This review summarizes the history and development of this innovative dry eye treatment from its initial use as an effective stomach medication to its current use in the treatment of dry eye in Japan.

show abstract

Section: Rebamipide For Clinical Applicationmentioning

confidence: 94%

“…Promotional and commercial use of the material in print, digital or mobile device format is prohibited without the permission from the publisher Lippincott Williams & Wilkins. Please contact journalpermissions@lww.com for further information 60. Copyright © 2013.…”

Section: Figurementioning

confidence: 99%

Rebamipide ophthalmic suspension for the treatment of dry eye syndrome: a critical appraisal

Kashima¹,

Itakura²,

Akiyama³

et al. 2014

OPTH

View full text Add to dashboard Cite

show abstract

“…Administration of topical rebamipide increases secretion of mucins from goblet cells and improves the ocular surface in short break-up time type of dry eye 1,2. The human eyelid margin looks histologically to be an important structure for the maintenance of tear film 3.…”

Section: Introductionmentioning

confidence: 99%

“…Recently, the clinical effects of rebamipide eye drops (Mucosta® ophthalmic suspen sion UD2%; Otsuka Pharmaceutical Co, Ltd, Tokyo, Japan) for various types of dry eye were reported 1,2,23,24. Rebamipide eye drops for dry eye are also being developed for approval in the US.…”

Section: Introductionmentioning

confidence: 99%

Topical rebamipide improves lid wiper epitheliopathy

Itakura¹,

Kashima²,

Itakura³

et al. 2013

OPTH

View full text Add to dashboard Cite

Administration of topical rebamipide increases the mucin level of tear film and improves the ocular surface in short break-up time type of dry eye. Lid wiper epitheliopathy (LWE) is a disorder of the marginal conjunctiva of the upper eyelid with dry eye symptoms. LWE may be related to mechanical forces during blinking resulting in inflammation of the ocular surface. Rebamipide also has various anti-inflammatory effects. In this report, we tried treatment with topical rebamipide for two cases of LWE. One case had been treated with sodium hyaluronate ophthalmic solution and diquafosol sodium eye drops by other doctors for several weeks. The other case was not previously treated. In both cases, fluorescein staining of the cornea and lid margin was remarkably improved, ocular symptoms decreased, and tear film break-up times increased with rebamipide eye drops four times daily for 2-3 weeks. Topical rebamipide was effective for corneal and conjunctival disorders in LWE. This drug may provide a novel approach to the treatment of LWE.

show abstract

“…32 A series prospective studies have demonstrated that rebamipide suspension has significant effect of improving fluorescein corneal staining, lissamine green conjunctival staining, Schirmer's test, tear-film breakup time, and dry eye-related ocular symptoms without serious adverse reaction. 31,[33][34][35] Meanwhile, there is increasing evidence that the excessive expression of inflammatory mediators, such as IL-8, IL-6, IL-1β, and TNF-α, on the ocular surface may have an important role in DES pathogenesis and clinical symptoms. [36][37][38] These cytokines promote the activation and migration of leukocytes, the expansion of pathogenic T cells and the production of other proinflammatory factors that mediate DES.…”

Section: Discussionmentioning

confidence: 99%

Anti-inflammatory effects of hinokitiol on human corneal epithelial cells: an in vitro study

et al. 2015

Eye

View full text Add to dashboard Cite

show abstract

Effect of Rebamipide Ophthalmic Suspension on Optical Quality in the Short Break-up Time Type of Dry Eye

Abstract: Rebamipide administered to treat the short BUT type of dry eye significantly improved optical quality because of the improvement in tear stability.

Cited by 52 publications

References 26 publications

Rebamipide ophthalmic suspension for the treatment of dry eye syndrome: a critical appraisal

Rebamipide ophthalmic suspension for the treatment of dry eye syndrome: a critical appraisal

Topical rebamipide improves lid wiper epitheliopathy

Anti-inflammatory effects of hinokitiol on human corneal epithelial cells: an in vitro study

Contact Info

Product

Resources

About